内镜与手术治疗减重连续管理中的真实世界体重下降图谱
该回顾性队列研究纳入2825例接受ESG、SG、RYGB或BPD-DS的成人,比较12个月总体重下降百分比(TBWL%)。结果显示TBWL%随手术强度递增而显著增加,但EWL%差异较小,提示指标选择影响疗效解读。
要点
- 12个月TBWL%:ESG 14.1%,SG 23.6%,RYGB 31.0%,BPD-DS 36.8%(p<0.001)。
- 术式是TBWL的最强独立预测因子,年轻、女性、无糖尿病、较低基线BMI亦与更多减重相关。
- TBWL%随术式强度明显分层,但EWL%差异较小,尤其RYGB与BPD-DS之间。
核心结论
- 内镜与不同术式减重干预在1年时呈现各自不同但有重叠的体重下降轮廓。
- 绝对TBWL%因术式而异,但EWL%趋同,反映基线肥胖程度的影响及指标选择的重要性。
研究设计与样本
- 单中心回顾性队列研究,纳入连续接受ESG、SG、RYGB或BPD-DS的成人患者。
- 共2825例,女性79.3%,平均年龄47.5±11.9岁,平均基线BMI 45.6±7.9 kg/m2。
- 排除同期使用抗肥胖药物治疗者,主要终点为12个月(±2个月)TBWL%。
主要发现
- 12个月平均TBWL%:ESG 14.1±9.3%,SG 23.6±9.4%,RYGB 31.0±8.3%,BPD-DS 36.8±8.7%(p<0.001)。
- 达到更高分类TBWL阈值(>10%至>30%)的可能性随手术强度增加而升高。
- EWL%在各术式间分离程度较小,尤其RYGB与BPD-DS之间。
- 校正分析中术式是TBWL的最强独立预测因子(p<0.001),年轻、女性、无糖尿病、较低基线BMI亦与更多减重相关。
临床怎么用
- 可为患者个体化选择内镜或不同减重术式提供1年体重下降的实践基准。
- 解读疗效时需注意TBWL%与EWL%的差异,避免单一指标误导决策。
局限性
- 单中心回顾性设计,可能存在选择偏倚。
- 排除同期使用抗肥胖药物者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a chronic, relapsing disease for which lifestyle and pharmacologic therapies, including glucagon-like peptide-1 receptor agonists, can achieve meaningful weight loss but are often limited by tolerability, access, and weight recurrence after discontinuation. Consequently, metabolic and bariatric interventions play a central role in the management of moderate to severe obesity. However, real-world comparative data spanning endoscopic and multiple surgical modalities remain limited. METHODS: We performed a retrospective cohort study of consecutive adults undergoing endoscopic sleeve gastroplasty (ESG), sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD-DS) at a single tertiary academic center. Patients with concurrent anti-obesity pharmacotherapy were excluded. The primary outcome was percent total body weight loss (TBWL%) at 12 months (± 2 months). Secondary outcomes included categorical TBWL thresholds (> 10%, > 15%, > 20%, > 25%, > 30%) and percent excess weight loss (EWL%). Multivariable linear regression was used to identify independent predictors of TBWL. RESULTS: Among 2,825 patients (79.3% female; mean age 47.5 ± 11.9 years; mean baseline BMI 45.6 ± 7.9 kg/m2), 183 underwent ESG, 699 SG, 1,813 RYGB, and 130 BPD-DS. Mean 12-month TBWL differed significantly by procedure (p < 0.001): ESG 14.1 ± 9.3%, SG 23.6 ± 9.4%, RYGB 31.0 ± 8.3%, and BPD-DS 36.8 ± 8.7%. The likelihood of achieving higher categorical TBWL increased with procedural intensity, whereas EWL values demonstrated less pronounced separation, particularly between RYGB and BPD-DS. In adjusted analyses, procedure type was the strongest independent predictor of TBWL (p < 0.001), with younger age, female sex, absence of diabetes, and lower baseline BMI also associated with greater weight loss. CONCLUSIONS: Endoscopic and surgical bariatric interventions are associated with distinct yet overlapping weight loss profiles at one year, reflecting differences in mechanism, invasiveness, and patient selection. While absolute TBWL varies across modalities, convergence in EWL highlights the influence of baseline adiposity and the importance of metric selection. These findings provide practical benchmarks to support individualized, patient-centered decision-making across the full continuum of metabolic therapies.
引用
- Ghusn W, Ghazal NE, Laplante SJ, et al. Mapping the continuum of procedural bariatric care: real-world weight loss after endoscopic and surgical interventions. Surg Endosc. 2026. PMID: 42277424. doi:10.1007/s00464-026-12933-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。